Your browser doesn't support javascript.
loading
Long-term results of photodynamic therapy or ranibizumab for polypoidal choroidal vasculopathy in LAPTOP study.
Miyamoto, Noriko; Mandai, Michiko; Oishi, Akio; Nakai, Shunichiro; Honda, Shigeru; Hirashima, Takafumi; Oh, Hideyasu; Matsumoto, Yoshiko; Uenishi, Mamoru; Kurimoto, Yasuo.
Afiliación
  • Miyamoto N; Department of Ophthalmology, Kobe City Eye Hospital, Kobe, Japan miyacy_fr@hotmail.com.
  • Mandai M; Department of Ophthalmology, Kobe City Medical Center General Hospital, Kobe, Japan.
  • Oishi A; Department of Ophthalmology, Kobe City Eye Hospital, Kobe, Japan.
  • Nakai S; Laboratory for Retinal Regeneration, RIKEN Center for Developmental Biology, Kobe, Japan.
  • Honda S; Department of Ophthalmology, Kobe City Medical Center General Hospital, Kobe, Japan.
  • Hirashima T; Department of Surgery, Division of Ophthalmology, Kobe University Graduate School of Medicine, Kobe, Japan.
  • Oh H; Department of Surgery, Division of Ophthalmology, Kobe University Graduate School of Medicine, Kobe, Japan.
  • Matsumoto Y; Department of Ophthalmology, Hyogo Prefectural Amagasaki General Medical Center, Amagasaki, Japan.
  • Uenishi M; Department of Ophthalmology, Hyogo Prefectural Amagasaki General Medical Center, Amagasaki, Japan.
  • Kurimoto Y; Department of Ophthalmology, Mitsubishi Kobe Hospital, Kobe, Japan.
Br J Ophthalmol ; 103(6): 844-848, 2019 06.
Article en En | MEDLINE | ID: mdl-30077969
BACKGROUND/AIM: We previously reported that ranibizumab performed better on visual prognosis than photodynamic therapy (PDT) in a Ranibizumab (Lucentis) And Photodynamic Therapy On Polypoidal choroidal vasculopathy (LAPTOP) study. To determine if the first-choice treatment, either PDT or intravitreal ranibizumab, has a long-term effect in patients with polypoidal choroidal vasculopathy (PCV). METHODS: We reviewed medical records of patientsrandomised to either PDT (29 eyes) or ranibizumab (27 eyes) from July 2009 to June 2011 in LAPTOP study. Retreatment or switching to other treatments were at the investigator's discretion after release from the 2-year LAPTOP study up to 5years. We evaluated visual acuity (VA), continuity of initial treatment, percentage of dry macula achievement and macular atrophy at 5 years. RESULTS: The logarithm of minimal angle of resolution VA was 0.56 in the PDT and 0.44 in the ranibizumab groups at baseline (p=0.101) and was 0.55 and 0.28 at 5years, respectively (p<0.05). More than 70% of the patients converted to aflibercept in following years. Achievement percentages of dry macula were 74% (PDT) and 63% (ranibizumab) at 5years, and macular atrophy was detected in 78% (PDT) and 60% (ranibizumab) with a mean area of 7.7 and 3.5 mm2, respectively (p=0.155). CONCLUSIONS: The better VA in the initial ranibizumab group compared with the PDT group at 2 years was retained at the 5-year follow-up.
Asunto(s)
Palabras clave
Texto completo
Añadir a Mi BVS
Imprimir
XML
PubMed Links
Buscar en Google

Texto completo: 1 Colección: 01-internacional Base de datos: MEDLINE Asunto principal: Fotoquimioterapia / Pólipos / Agudeza Visual / Enfermedades de la Coroides / Coroides / Ranibizumab / Verteporfina Tipo de estudio: Diagnostic_studies / Observational_studies / Prognostic_studies Límite: Humans Idioma: En Revista: Br J Ophthalmol Año: 2019 Tipo del documento: Article País de afiliación: Japón Pais de publicación: Reino Unido
Texto completo
Añadir a Mi BVS
Imprimir
XML
PubMed Links
Buscar en Google

Texto completo: 1 Colección: 01-internacional Base de datos: MEDLINE Asunto principal: Fotoquimioterapia / Pólipos / Agudeza Visual / Enfermedades de la Coroides / Coroides / Ranibizumab / Verteporfina Tipo de estudio: Diagnostic_studies / Observational_studies / Prognostic_studies Límite: Humans Idioma: En Revista: Br J Ophthalmol Año: 2019 Tipo del documento: Article País de afiliación: Japón Pais de publicación: Reino Unido